Reported 1 day ago
This article discusses a bullish outlook for Liquidia Corporation (LQDA), highlighting its recent successful drug launch with significant sales potential. As of September 9, LQDA's share price was $27.80 and its first-month sales of 224 prescriptions could translate to $322 million in annual revenue. With competitors like United Therapeutics, LQDA has a considerable market to target, and investor sentiment may grow due to comparisons with successful companies like Verona Pharma. Overall, LQDA shows promise for growth despite potential near-term volatility.
Source: YAHOO